By Editor , 14 October 2026 Inhibrx Sets Four Oncology Data Presentations Across Three Meetings San Diego – – October 13, 2026 -- Inhibrx Biosciences (Nasdaq: INBX) will present phase 2 data on both clinical-stage candidates in its pipeline in four sessions at three oncology conferences between Oct. 25 and Nov. 20, 2026.
